|
|
|
|
|
|
|
23.12.25 - 11:01
|
Performance-Turbo 2026: Diese Aktien gehören jetzt auf die Watchlist (Tim Schaefer)
|
|
|
Welche Aktien starten 2026 durch? Entdecke 3 aussichtsreiche Kandidaten von NVIDIA bis Bristol-Myers Squibb. Analyse zu Growth, Value und Dividenden für dein Depot. Jetzt lesen auf timschaefermedia.com!
Der Beitrag Performance-Turbo 2026: Diese Aktien gehören jetzt auf die Watchlist erschien zuerst auf Tim Schäfer Media....
|
|
|
|
|
|
|
20.12.25 - 09:12
|
Trump strikes deal with US drugmakers to cut Medicaid medicine costs (The Guardian)
|
|
|
Officials pledge 'massive savings' as companies agree to offer drugs at prices paid in other wealthy countriesDonald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche's US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on. Continue reading......
|
|
|
|
|
|
|
|
|
19.12.25 - 21:21
|
Neun weitere Pharma-Unternehmen senken Preise in den USA (Dow Jones)
|
|
|
eun Pharmaunternehmen wollen in den USA die Preise senken. Die Gesellschaften haben sich gegenüber der US-Regierung bereit erklärt, bestimmte US-Preise für ihre Medikamente zu senken. Die Unternehmen stimmten zu, die US-Preise für Medikamente auf ein Niveau zu senken, das mit den Preisen in anderen wohlhabenden Ländern vergleichbar ist, die im Allgemeinen viel niedriger sind. Diese "Meistbegünstigten"-Preise gelten für das US-Medicaid-Programm für Patienten mit geringerem Einkommen, für Direkt-an-Patienten-Dienste einschließlich des geplanten TrumpRx und für neu eingeführte Medikamente in der Zukunft..
|
|
|
|
|
18.12.25 - 13:00
|
Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026 (Business Wire)
|
|
|
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and f...
|
|
|
18.12.25 - 10:48
|
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field (GlobeNewswire EN)
|
|
|
MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subsequent offering period (the “Subsequent Offering Period”) of the exchange offer (the “Offer”) for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time. With the successful acquisition, BioNTech intends to further complement its capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. The acquisition builds on BioNTech's proven track record and established position in the global mRNA industry and supports the execution of the Company's oncology strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 and VEGF-A, which is being jointly developed with Bristol Myers Squibb Company (NYSE: BMY, “BMS”)....
|
|
|
|
|
|
|
|
|
|
|
|
|
15.12.25 - 21:30
|
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored (Benzinga)
|
|
|
Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and improving risk-reward outlook.
Latest Ratings for BMY
DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnBuy Dec 2021Wells FargoInitiates Coverage OnEqual-Weight
View More Analyst Ratings for BMY
View the Latest Analyst Ratings
read more...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
